Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 330

1.

All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy.

Okin PM, Kjeldsen SE, Julius S, Hille DA, Dahlöf B, Edelman JM, Devereux RB.

Eur Heart J. 2010 Sep;31(18):2271-9. doi: 10.1093/eurheartj/ehq225. Epub 2010 Jul 2.

PMID:
20601389
2.

Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.

Okin PM, Wachtell K, Kjeldsen SE, Julius S, Lindholm LH, Dahlöf B, Hille DA, Nieminen MS, Edelman JM, Devereux RB.

Circ Arrhythm Electrophysiol. 2008 Dec;1(5):337-43. doi: 10.1161/CIRCEP.108.795351. Epub 2008 Dec 2.

3.

Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.

Okin PM.

J Electrocardiol. 2009 Nov-Dec;42(6):584-8. doi: 10.1016/j.jelectrocard.2009.06.020. Epub 2009 Jul 24.

PMID:
19631946
4.

Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).

Okin PM, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Nieminen MS, Edelman JM, Dahlöf B, Devereux RB; LIFE Study Investigators.

Circulation. 2009 Apr 14;119(14):1883-91. doi: 10.1161/CIRCULATIONAHA.108.812313. Epub 2009 Mar 30.

5.

Serial assessment of the electrocardiographic strain pattern for prediction of new-onset heart failure during antihypertensive treatment: the LIFE study.

Okin PM, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Nieminen MS, Edelman JM, Dahlöf B, Devereux RB; LIFE Study Investigators.

Eur J Heart Fail. 2011 Apr;13(4):384-91. doi: 10.1093/eurjhf/hfq224. Epub 2011 Jan 14.

6.

Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.

Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlöf B; LIFE Study Investigators.

JAMA. 2004 Nov 17;292(19):2343-9.

PMID:
15547161
7.

Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.

Okin PM, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Dahlöf B; LIFE Study Investigators.

Ann Intern Med. 2007 Sep 4;147(5):311-9.

PMID:
17785486
8.

Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.

Okin PM, Devereux RB, Gerdts E, Snapinn SM, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Lindholm LH, Dahlöf B; LIFE Study Investigators.

Circulation. 2006 Mar 28;113(12):1588-96. Epub 2006 Mar 13.

9.

Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients.

Okin PM, Devereux RB, Nieminen MS, Jern S, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Julius S, Snapinn S, Dahlöf B; LIFE Study Investigators.

Hypertension. 2004 Jul;44(1):48-54. Epub 2004 Jun 1.

10.

Impact of lower achieved blood pressure on outcomes in hypertensive patients.

Okin PM, Hille DA, Kjeldsen SE, Dahlöf B, Devereux RB.

J Hypertens. 2012 Apr;30(4):802-10; discussion 810. doi: 10.1097/HJH.0b013e3283516499.

PMID:
22343536
11.
12.

Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.

Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Lindholm LH, Nieminen MS, Edelman JM, Hille DA, Dahlöf B.

JAMA. 2006 Sep 13;296(10):1242-8.

PMID:
16968848
13.

Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.

Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Dahlof B; Losartan Intervention for Endpoint reduction in hypertension Study Investigations.

Circulation. 2003 Aug 12;108(6):684-90. Epub 2003 Jul 28.

14.

QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study.

Oikarinen L, Nieminen MS, Viitasalo M, Toivonen L, Jern S, Dahlöf B, Devereux RB, Okin PM; LIFE Study Investigators.

Hypertension. 2004 May;43(5):1029-34. Epub 2004 Mar 22.

15.

Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.

Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, Aurup P, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Rokkedal J, Devereux RB.

J Am Coll Cardiol. 2005 Mar 1;45(5):705-11.

16.

Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.

Wachtell K, Okin PM, Olsen MH, Dahlöf B, Devereux RB, Ibsen H, Kjeldsen SE, Lindholm LH, Nieminen MS, Thygesen K.

Circulation. 2007 Aug 14;116(7):700-5. Epub 2007 Jul 30.

17.

Persistence of left ventricular hypertrophy is associated with increased cardiovascular morbidity and mortality in hypertensive patients with lower achieved systolic pressure during antihypertensive treatment.

Okin PM, Hille DA, Kjeldsen SE, Dahlöf B, Devereux RB.

Blood Press. 2014 Apr;23(2):71-80. doi: 10.3109/08037051.2013.791414. Epub 2013 May 31.

PMID:
23721506
18.

Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure.

Okin PM, Wachtell K, Gerdts E, Dahlöf B, Devereux RB.

J Hypertens. 2014 Dec;32(12):2472-8; discussion 2478. doi: 10.1097/HJH.0000000000000432.

PMID:
25340854
19.

Effect of changing heart rate during treatment of hypertension on incidence of heart failure.

Okin PM, Kjeldsen SE, Julius S, Hille DA, Dahlöf B, Devereux RB.

Am J Cardiol. 2012 Mar 1;109(5):699-704. doi: 10.1016/j.amjcard.2011.10.026. Epub 2011 Dec 10.

PMID:
22154318
20.

In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.

Wachtell K, Gerdts E, Aurigemma GP, Boman K, Dahlöf B, Nieminen MS, Olsen MH, Okin PM, Palmieri V, Rokkedal JE, Devereux RB.

Blood Press. 2010 Jun;19(3):169-75. doi: 10.3109/08037051.2010.481811.

PMID:
20438307

Supplemental Content

Support Center